Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NACDS president Hannan

This article was originally published in The Tan Sheet

Executive Summary

Robert Hannan has been named interim president & CEO of the National Association of Chain Drug Stores, effective April 3, the organization announces March 31. Hannan, a veteran in the chain drug industry with over 40 years experience, has served as president of Thrift Drug and vice chairman of Eckerd Drug after its acquisition of the Thrift Drug chain, according to NACDS. Having since retired from the industry, he currently runs his own consulting firm, Hannan Executive Services, Inc. The exec previously served as interim NACDS president in 1999. Hannan replaces Craig Fuller, who resigned as president & CEO March 20 (1"The Tan Sheet" March 27, 2006, In Brief). Exec VP & COO Bill Sittmann, who served in the White House with Fuller under Bush and Reagan, also resigned from NACDS March 31...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel